- Home
- Publications
- Publication Search
- Publication Details
Title
Why 90% of clinical drug development fails and how to improve it?
Authors
Keywords
-
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-11
DOI
10.1016/j.apsb.2022.02.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
- (2021) Xin Luan et al. BIOMATERIALS
- Positron emission tomographic imaging in drug discovery
- (2021) Krishna Kanta Ghosh et al. DRUG DISCOVERY TODAY
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
- (2021) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- Highly accurate protein structure prediction with AlphaFold
- (2021) John Jumper et al. NATURE
- Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models
- (2021) Jiashun Mao et al. iScience
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips
- (2020) Anna Herland et al. Nature Biomedical Engineering
- Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
- (2020) Duxin Sun AAPS Journal
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities
- (2020) Karen D. Davis et al. Nature Reviews Neurology
- Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades
- (2020) Michael Davies et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery
- (2020) Izumi V. Hinkson et al. Frontiers in Pharmacology
- What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
- (2020) Duxin Sun et al. ACS Nano
- Methods to Optimize CNS Exposure of Drug Candidates
- (2020) Nandini C. Patel BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
- (2020) Wen-Hao Guo et al. Nature Communications
- Molecular representations in AI-driven drug discovery: a review and practical guide
- (2020) Laurianne David et al. Journal of Cheminformatics
- Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
- (2020) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Improving target assessment in biomedical research: the GOT-IT recommendations
- (2020) Christoph H. Emmerich et al. NATURE REVIEWS DRUG DISCOVERY
- Innovative approaches in CNS drug discovery
- (2020) Mathieu Charvériat et al. THERAPIE
- Applications of machine learning in drug discovery and development
- (2019) Jessica Vamathevan et al. NATURE REVIEWS DRUG DISCOVERY
- Trends in clinical success rates and therapeutic focus
- (2019) Helen Dowden et al. NATURE REVIEWS DRUG DISCOVERY
- Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities
- (2019) Donglu Zhang et al. DRUG METABOLISM AND DISPOSITION
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
- (2019) Ann Lin et al. Science Translational Medicine
- Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumours
- (2018) Qin Dai et al. ACS Nano
- The Current Status of Drug Discovery and Development as Originated in US Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development
- (2018) Tohru Takebe et al. CTS-Clinical and Translational Science
- Cellular target engagement: a new paradigm in drug discovery
- (2018) Ivan Babic et al. Future Medicinal Chemistry
- Nonlinear Protein Binding: Not What You Think
- (2018) Amelia N. Deitchman et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective
- (2018) John L. Vahle et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches
- (2018) Nilanjan Adhikari et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Advances in organ-on-a-chip engineering
- (2018) Boyang Zhang et al. Nature Reviews Materials
- Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals
- (2018) Terry R. Van Vleet et al. SLAS Discovery
- Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs
- (2018) Oleg A. Raevsky et al. CURRENT MEDICINAL CHEMISTRY
- Artificial intelligence in drug development: present status and future prospects
- (2018) Kit-Kay Mak et al. DRUG DISCOVERY TODAY
- Optimization techniques for novel c-Met kinase inhibitors
- (2018) Zhi-Gang Sun et al. Expert Opinion on Drug Discovery
- Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery
- (2017) Balaguru Ravikumar et al. Expert Opinion on Drug Discovery
- Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
- (2017) Aeri Kim et al. Journal of Breast Cancer
- Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
- (2017) Yan Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanistic enzymology in drug discovery: a fresh perspective
- (2017) Geoffrey A. Holdgate et al. NATURE REVIEWS DRUG DISCOVERY
- Opportunities and challenges in phenotypic drug discovery: an industry perspective
- (2017) John G. Moffat et al. NATURE REVIEWS DRUG DISCOVERY
- A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1
- (2017) Dean E. McNulty et al. SLAS Discovery
- In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs
- (2016) Barry R. Campbell et al. ILAR JOURNAL
- The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro -to- In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research
- (2016) Patrick Poulin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Phase II and phase III failures: 2013–2015
- (2016) Richard K. Harrison NATURE REVIEWS DRUG DISCOVERY
- Cornerstones of CRISPR–Cas in drug discovery and therapy
- (2016) Christof Fellmann et al. NATURE REVIEWS DRUG DISCOVERY
- PBPK modeling and simulation in drug research and development
- (2016) Xiaomei Zhuang et al. Acta Pharmaceutica Sinica B
- Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research
- (2015) Patrick Poulin JOURNAL OF PHARMACEUTICAL SCIENCES
- High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
- (2014) Oscar Arrieta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An overview of current and emerging SERMs
- (2014) Barry S. Komm et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Microfluidic organs-on-chips
- (2014) Sangeeta N Bhatia et al. NATURE BIOTECHNOLOGY
- Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
- (2013) D. Gonzalez et al. CLINICAL MICROBIOLOGY REVIEWS
- Considering the impact drug-like properties have on the chance of success
- (2013) Iskander Yusof et al. DRUG DISCOVERY TODAY
- Plasma protein binding: From discovery to development
- (2013) Tonika Bohnert et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
- (2013) James Kramer et al. Scientific Reports
- Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
- (2012) A. Inoue et al. ANNALS OF ONCOLOGY
- The Science and Business of Drug Discovery: Demystifying the Jargon. By Edward D. Zanders.
- (2012) Klaus Müller ChemMedChem
- Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder
- (2012) David Michelson et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The determination and interpretation of the therapeutic index in drug development
- (2012) Patrick Y. Muller et al. NATURE REVIEWS DRUG DISCOVERY
- Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
- (2011) Richard Hargreaves et al. Annals of the New York Academy of Sciences
- Positron emission tomography molecular imaging for drug development
- (2011) Paul M. Matthews et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of Recovery on Fraction Unbound Using Equilibrium Dialysis
- (2011) Li Di et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Principles of early drug discovery
- (2010) JP Hughes et al. BRITISH JOURNAL OF PHARMACOLOGY
- Activity Landscape Representations for Structure−Activity Relationship Analysis
- (2010) Anne Mai Wassermann et al. JOURNAL OF MEDICINAL CHEMISTRY
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Active-Site Concentrations of Chemicals - Are They a Better Predictor of Effect than Plasma/Organ/Tissue Concentrations?
- (2009) Margareta Hammarlund-Udenaes BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Human radiolabeled mass balance studies: objectives, utilities and limitations
- (2009) Natalia Penner et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Drug-Like Property Concepts in Pharmaceutical Design
- (2009) Li Di et al. CURRENT PHARMACEUTICAL DESIGN
- Virtual screening of chemical libraries for drug discovery
- (2008) Darren VS Green Expert Opinion on Drug Discovery
- General approach for the calculation of tissue to plasma partition coefficients
- (2007) Walter Schmitt TOXICOLOGY IN VITRO
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now